Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
How virus affected breast screening Europe-wide
Thurs October 1st - The pressure on breast screening programmes across many European countries during the COVID-19 pandemic could lead to an increase in deaths from cancer, a conference will hear today. More
Care homes to test anti-inflammatory virus treatment
Thurs October 1st - An anti-tumour necrosis factor drug is to be tested as a community treatment for COVID-19 infection, it has been announced. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

Immunotherapy hope for elimination of leukaemia stem cells

Friday May 22nd, 2020

Hematopoietic stem cells can be selectively eliminated using immunotherapy instead of chemotherapy, a new Swiss study has revealed.

Researchers led by the University of Zurich report that this can be achieved using healthy and cancerous haematopoietic stem cells from humans in mice. They now want to test the new immunotherapy in humans as soon as possible.

Acute myeloid leukaemia patients are usually treated with intensive chemotherapy and sometimes radiotherapy, after which they require a transplant of hematopoietic stem cells from a healthy donor.

However, there are serious side effects associated with the treatment, making it unsuitable for many patients.

Writing in Leukaemia, the team of scientists and physicians from the University of Zurich, the University Hospital Zurich and ETH Zurich reveal they have used CAR-T therapy to eliminate the leukaemic and hematopoietic stem cells more selectively.

Study leader Professor Markus Manz, professor of medicine at UZH and director of the Department of Medical Oncology and Haematology at USZ, said: “Compared to normal strategies, our method works very selectively, meaning that mature blood cells and other tissues are spared.”

The results were achieved using cell cultures in the lab and in mice with human blood and cancer cells, but Professor Manz is confident that the treatment could also be effective in humans.

“The principle works: It is possible to eliminate, with high precision, the leukaemic and hematopoietic stem cells in a living organism,” he said.

Researchers are now testing to see if the method is only possible with CAR-T cells or also with simpler constructs, such as T-cell-activating antibodies.

Prof Manz said if the method also works with humans, it could replace chemotherapy.

Source: Myburgh R, Kiefer JD, Russkamp NF, et al. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukaemia 1 May 2020; doi: 10.1038/s41375-020-0818-9.

Tags: Cancer | Europe

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)